Treatment of adverse effects associated with administration of extracellular hemoglobin
US5750132A · kind A · utility
5Cited by
9References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 26, 1995 |
| Grant date | May 12, 1998 |
| Priority date | — |
| Expiry date | May 26, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of lessening the severity and frequency of adverse effects associated with administration of extracellular hemoglobin comprising administration of a smooth muscle relaxant. Preferred smooth muscle relaxants are terbutaline and nifedipine, which can be administered in a prophylactic treatment, responsive regimented treatment or responsive intermittent treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.